Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for Treatment of Myeloma Patients Presenting with Extramedullary Disease. The Antares Study
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site, you agree to our use of cookies.OkPrivacy policy
